On May 27, 2022, the FDA accelerated the approval of a new indication for the CD19-directed CAR T-cell therapy tisagenlecleucel (Kymriah; Novartis) for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication an orphan drug designation.
The approval was based on the ELARA study, a multicenter, single-arm, open-label clinical trial of adults with relapsed or refractory follicular lymphoma within 6 months after completion of ≥2 lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or relapsed after autologous hematopoietic stem-cell transplant.
The main efficacy measures were overall response rate (ORR) and duration of response (DOR). Among the 90 patients in the primary efficacy analysis, the ORR was 86% (95% confidence interval [CI], 77-92), including 68% complete responses. At 9 months, the median DOR was not reached, and 75% of those with a response were still responding to the CAR T-cell therapy. For the 98 patients who underwent leukapheresis, the ORR was 86% (95% CI, 77-92), including 67% complete responses.
The most common (>20%) adverse reactions were cytokine-release syndrome, infection, fatigue, musculoskeletal pain, headache, and diarrhea.
Continued approval for this new indication may be contingent on verification of the clinical benefit in confirmatory trial(s).
To sign up for our newsletter or print publications, please enter your contact information below.